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Abdominal obesity is a major risk factor to attract the insulin resistance syndrome. It is proposed that abdominal obesity exposes the
liver to elevated levels of free fatty acids, which activate a neuroendocrine reflex, leading to increased circulating levels of
glucocorticoids. Besides directly attenuating peripheral insulin signaling, glucocorticoids oppose the activity of central nervous
regulatory systems that stimulate insulin action. Among the factors that promote insulin action is leptin. Leptin regulates peripheral fuel
partitioning and insulin action mainly through hypothalamic neuronal networks, which in turn, regulate endocrine activity of adipose
tissue in a way comparable to thiazolidinediones. These are a class of insulin-sensitizing drugs, which exert their antidiabetic effects
through the gamma isoform of peroxisome proliferator-activated receptor (PPAR-g). Since glucocorticoids oppose leptin action at
several levels of control (including the central nervous system, CNS), it is argued that subjects easily develop obesity and associated
metabolic disorders.
D 2003 Elsevier B.V. All rights reserved.Keywords: Fatty acid; Glucocorticoid; Leptin; Adiponectin; PPARg (peroxisome proliferator-activated receptor); Hypothalamus1. Introduction
Many species, including rodents and primates, eat their
food in bouts (i.e., meals) that are interspaced by time
intervals of different durations. This strategy is considered
quite advantageous, since it allows animals to display a
variety of behaviors of different intensities during the inter-
meal interval. Some of these may be crucial for survival,
and could have ultimately influenced the evolutionary
success of some species. One implication of food eaten in
short bouts is that the absorbed amount of fuels during and
after a meal should greatly exceed direct metabolic require-
ments (Strubbe and van Dijk, 2002). To this end, the ‘milieu
interieur’ is put at risk because food intake-associated fuel
excursions can have deleterious effects on metabolic (e.g.,0014-2999/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.ejphar.2003.08.090
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E-mail address: g.van.dijk@biol.rug.nl (G. van Dijk).glycosylation causing loss of enzymatic efficacy) and
cardiovascular (e.g., triglyceride and cholesterol accumula-
tion, atherosclerosis, high blood pressure, etc.) systems
(Preus, 1997; Sowers and Epstein, 1995). In order to
dampen fuel excursions in the general circulation associated
with food intake, evolution has provided most higher
species with an intricate system, which effectively stores
absorbed nutrients into reserve tissues (Woods et al., 1984).
The pancreas, and in particular one of its endocrine factors,
insulin, plays a key role in this process. Among several
nutrients (including several carbohydrates, fatty-, and amino
acids), of which the levels are elevated in the circulation
during and following a meal, a rise in the ambient circu-
lating glucose level is a particularly strong stimulus to
secrete insulin into the blood stream. Increased insulin
secretion can already occur when food enters the pharyn-
geal cavity, and thus before fuels actually rise in the
circulation (Strubbe and Steffens, 1975). This so-called
‘‘cephalic phase’’ of insulin secretion, together with the
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optimised storage of energy fuels in the form of glycogen
in liver and muscle, and of triglycerides in adipose tissue
(Woods et al., 1984).
During inter-meal intervals, stored fuels can be released
again and deliver energy required for metabolic purposes,
such as tissue maintenance, heat production, muscle move-
ment, etc. Lowering of insulin secretion is a major contrib-
utor to the release of glucose from the liver, thereby
supplying energy to the central nervous system (CNS) and
peripheral tissues. In particular, the CNS needs a constant
supply of glucose, since glucose is a requisite fuel for the
brain (Woods et al., 1984). In addition, a gradual decline in
insulin secretion stimulates free fatty acid release from
adipose tissue, and free fatty acids can be utilized efficiently
by peripheral organs and tissues through the h-oxidation
pathway (Strubbe and Prins, 1986). The fall in insulin
secretion also contributes to the release of regulatory hor-
mones which stimulate hepatic gluconeogenesis. This latter
mechanism is important in the face of continued starvation,
since hepatic glycogen stores are depleted after 1 or 2 days.
Adipose tissue, on the other hand, is able to meet ongoing
energy demands for several weeks, and thus becomes the
main source of energy in the event of continued starvation
(Cahill et al., 1966).
Given the important roles of insulin in the regulation of
fuel fluxes in the body, it can be imagined that failure of
the pancreas to secrete insulin, for example due to auto-
immune destruction of the pancreatic B-cells (i.e., type-I
Diabetes Mellitus), is perhaps one of the most drastic
metabolic diseases known to date. As there is no cure for
type-I Diabetes Mellitus, patients suffering from this
disease are left with insulin replacement therapy. Another
form of this disease is characterized by severe tissue
resistance to insulin. At an early stage of this disease,
absorbed nutrients associated with food intake require
much more insulin to be stored into the reserve tissues.
At a later stage, this has been proposed to underlie loss of
B-cell functioning and concomitant hyperglycemia (Lin-
gohr et al., 2002), a condition that is referred to as type II
Diabetes Mellitus. Whereas type-II Diabetes Mellitus is
traditionally regarded as a disease of the elderly, the
incidence of this disease in young adults and even
children is currently increasing (Rosenbloom et al.,
1999). Up to 50–80% of subjects worldwide with Diabe-
tes Mellitus are obese depending upon ethnic background
and community. Some studies have shown that the occur-
rence of type II diabetes among obese individuals is more
than 5–10 times higher than in normal weight individuals
(Zimmet et al., 2001). Besides being often hyperphagic
and obese, insulin-resistant subjects are frequently dyslipi-
demic, hypertensive (or have other cardiovascular compli-
cations), and have disturbances in neuroendocrine axis
(Bjorntorp, 1992). The present review focuses on some
of the potential mechanism that may relate these factors to
insulin resistance.2. Role of fat deposition in peripheral insulin action
2.1. Free fatty acids
The increased prevalence of the insulin resistance
syndrome and obesity has paralleled the prosperity of
our western-industrialized society, and therefore might be
considered lifestyle-induced diseases. The most frequently
mentioned factors that propel them are an increase in
dietary fat intake in combination with a sedentary exis-
tence. Among the three macronutrients, i.e., fat, carbohy-
drate, and protein, fat indeed has the lowest satiety index
and the highest caloric density (Flatt, 1986; Rolls et al.,
1994), and thus would cause the largest weight gain in the
form of stored body fat. Increased body fat, particularly
the abdominal type, is often associated with increased
lipolysis and elevated plasma levels of free fatty acids
(Jensen et al., 1989). At present, it is becoming increas-
ingly clear that chronic exposure to elevated plasma levels
of free fatty acids can lead to elevated triglyceride content
inside a number of organs and tissues other than adipose
tissue (Boden and Shulman, 2002). In turn, intracellular
free fatty acids in these non-adipose organs can interfere
with the cellular mechanisms of insulin signaling and
down-regulate cellular sensitivity to insulin (Shullman,
2002). This idea is corroborated by cross-sectional studies
in humans using 1H magnetic resonance spectroscopy
where insulin resistance correlated strongly with the intra-
myocellular lipid concentration (e.g., Perseghin et al.,
1999). Dobbins et al. (2001) observed that the interaction
between increased free fatty acid exposure in rats caused
by high-fat feeding and the development of insulin resis-
tance is stronger when muscular h-oxidation of fatty acids
is reduced. Thus, increased triglyceride content in muscle
due to increased loading as well as reduced breakdown
might be considered high-risk factors for the development
of insulin resistance (Boden, 1997).
Besides interfering with muscular tissue sensitivity to
insulin, free fatty acids are also known to affect the liver.
It has for example been shown that experimental elevation
of the plasma free fatty acid level increases hepatic
glucose production and this is particularly due to a rise
in gluconeogenesis (Roden et al., 2000). This may con-
tribute to hyperglycemia and increased insulin production
in type-II diabetic patients. Increased cholesterol synthesis
has been observed under conditions of elevated plasma
free fatty acid levels as well (Adeli et al., 2001). Since
abdominal fat drains on the hepatic portal circulation, it
seems reasonable to believe that increased abdominal fat
deposition might particularly expose the liver to elevated
free fatty acid levels, which in turn can causes hepatic
insulin resistance (Bjorntorp, 1992). Consistent with this
idea is the finding that surgical removal of visceral fat
reverses hepatic insulin resistance in moderately obese
rats (Barzilai et al., 1999). Benthem et al. (2000)
exploited this idea further, and investigated whether
G. van Dijk et al. / European Journal ofexperimental elevation of the free fatty acid level in the
hepatic portal vein of rats could directly induce insulin
resistance in these animals. To this end, rats were chron-
ically infused during a 24-h interval with oleic acid into
the portal vein, and thereafter subjected to an intravenous
glucose tolerance test. Consistent with the hypothesis was
the finding that the plasma insulin concentration rose far
higher in response to the intravenous glucose tolerance
test relative to the control group whereas glucose levels
were equally increased, which is a strong indication of
reduced insulin sensitivity (see Fig. 1). The inhibitory
effects on insulin sensitivity were not observed upon
equimolar infusion of the medium-chain free fatty acid,
caprylate, into the hepatic portal vein, indicating that the
liver is more sensitive to long-chain fatty acids. The
infused oleate may have increased hepatic triglyceride
stores, which is presumably a committed step towards
hepatic insulin resistance. This idea is consistent with the
recent reports on the role of stearoyl-CoA desaturase
(SCD) in catalyzing the biosynthesis of mono-unsaturated
fatty acid enabling triglyceride synthesis. When fed a
high-fat diet, mice with a targeted disruption of the
SCD1 isoform had dramatically reduced hepatic triglycer-
ide storage as well as increased sensitivity to insulin and
an increased rate of lipid oxidation (Ntambi et al., 2002).
In addition, SCD1 disruption in mice was shown to
protect markedly against genetic obesity and concomitant
insulin resistance (Cohen et al., 2002).Fig. 1. (A) Plasma immunoreactive insulin (IRI) and blood glucose profiles in r
intraportal fatty acid infusions (150 nmol/min) over the 24-h preceding interval in m
min) on plasma corticosterone, norepinephrine, and epinephrine levels in male W
indicates a significant different relative to saline treatment.2.2. Glucocorticoids
Besides causing insulin resistance, feeding of a high-fat
diet is often associated with increases in neuroendocrine
activity, including that of the hypothalamo-pituitary adrenal
axis (Tannenbaum et al., 1997). Provided that high-fat
feeding increases the hepatic portal level of free fatty acids,
this observation is consistent with findings in the study of
Benthem et al. (2000) that hepatic portal oleic acid infusion
causes increases in the circulating levels of the sympathetic
transmitter, norepinephrine, and of corticosterone (see Fig.
1B). These latter effects were not observed following
hepatic portal administration of equimolar amounts of
caprylate, the medium-chain fatty acid. It is well known
that increased circulating levels of glucocorticoids induce
insulin resistance in peripheral tissues (Kusunoki et al.,
1995; Olefsky et al., 1975; Rizza et al., 1982), and increased
sympathetic activity might predispose to hypertension and
related cardiac diseases (Tuck, 1992; Grekin et al., 1997).
Thus, the findings in the study of Benthem et al. (2000)
reinforce the idea originally proposed by Bjorntorp (1992)
that increased levels of hepatic portal free fatty acids induce
a reflex activation involving the neuroendocrine system, and
this mechanism might contribute to the develoment of
insulin resistance and related metabolic and cardiovascular
derangements. Directly relevant to this idea is the finding by
Orbach and Andrews (1973) that vagal afferent activity is
increased following long-chain fatty acid infusion into the
Pharmacology 480 (2003) 31–42 33esponse to the intravenous glucose tolerance tests (16 mg/20 min) during
ale Wistar rats. (B) Effect of 24-h intraportal fatty acid infusion (150 nmol/
istar rats. All data are expressed as average change (F S.E.M.). Asterisk
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about the mechanism by which a potential signal related to
excess triglycerides and/or reduced lipid oxidation is able to
activate vagal and/or visceral afferents and ultimately rea-
ches the CNS. First of all, evidence from animal studies
suggests that the activity of hepatic vagal/visceral afferent
nerves can be modulated by metabolic processes within the
liver (Lutz et al., 1996; Friedman, 1988). Another possibil-
ity might be that elevated levels of hepatic portal free fatty
acids produce local inflammatory processes in the liver, and
these could activate vagal/visceral afferents as well (Volpes
et al., 1992). Consistent with this latter possibility is the
findings in the study of Benthem et al. (2000) that hepatic
portal oleic acid infusion caused an increase in plasma levels
of alanine aminotransferase, a marker previously found to
be associated with symptoms of syndrome X as well as
hepatic steatosis (Hollmann et al., 1997).
A potential signal conveyed within hepatic vagal affer-
ents could reach the brain stem, and in turn, could be
connected to the paraventricular hypothalamus, a brain
region known to regulate sympathetic outflow and activity
of the hypothalamo-pituitary adrenal axis (Sawchenko and
Swanson, 1981, 1985). Consistent with a role for vagal
afferent nerves in insulin sensitivity and neuroendocrine
activity are the findings of Koopmans et al. (1998), who
showed that destruction of unmyelinated afferent nerves
(including those from the liver) by the neural toxin capsaicin
in rats greatly improves glycemic control in these animals,
as well as markedly reduces the activity of the hypothalamo-
pituitary adrenal axis and the sympathetic nervous system.
Improved glycemic control by afferent neural destruction
could be achieved as well in dramatically obese and type-II
diabetic Zucker rats (Gram, 2003). Along other lines, Yuan
et al. (2001) found that Zucker rats chronically treated with
high doses of sodium salicylate augmented insulin sensitiv-
ity and improved glycemic control as well. Thus, while high
doses of salicylates might improve insulin sensitivity
through inhibition of the nuclear factor kappa B and its
upstream activator InB kinase h in peripheral tissues, these
doses of salicylates certainly block cyclooxygenases, which
are key enzymes involved in prostaglandin synthesis. The
latter pathway is the classical target of nonsteroidal anti-
inflammatory drugs such as aspirin. Since prostaglandins
are produced in the CNS in response to activation of a vagal
afferent pathway involving interleukins and corticotropin-
relasing hormone (Ericsson et al., 1997), blockade of this
pathway may result in reduced activation of the hypothal-
amo-pituitary-adrenal axis and the sympathetic nervous
system, and therefore would ameliorate the metabolic syn-
drome. While Yuan et al. (2001) have not directly assessed
the possibility that aspirin treatment affects neuroendocrine
parameters in Zucker rats, this mechanism might be plausi-
ble considering the fact that inhibitors of cyclooxygenases
have previously been shown to reduce the activity of the
hypothalamo-pituitary-adrenal axis (Parsadaniantz et al.,
2000). Important in this respect is the notion that Zuckerrats, as well as many other genetically obese rodents, have
an amplified activity of the hypothalamo-pituitary-adrenal
axis (Walker et al., 1992). Taken together, high plasma
levels of free fatty acids can underlie the insulin resistance
syndrome either directly in peripheral tissue or via a
stimulatory effect on activity of the hypothalamo-pituitary-
adrenal axis resulting in elevated levels of glucocorticoids.
It needs to be added that increased action of glucocorti-
coids leading to the insulin resistance syndrome can be
achieved even in the absence of increased circulating levels
of glucocorticoids. For example, cases have been reported
of obese humans who have normal glucocorticoid levels,
but with increased activity of 11-h-hydroxysteroid dehydro-
genase type 1 (11h-HSD) in fat tissue. 11 h-HSD plays a
crucial role in determining the intracellular glucocorticoid
concentrations by regenerating the active glucocorticoid
(cortisol in humans and corticosterone in rodents) from
inactive forms (Rask et al., 2001). Transgenic mice over-
expressing 11h-HSD in fat tissue consistently become
insulin-resistant, hyperlipidemic, and, surprisingly, also dis-
play hyperphagia despite increased body adiposity (Masu-
zaki et al., 2001). The mechanisms that control these
processes are currently under intense investigation, and
might involve a role for free fatty acids as well (Stulnig et
al., 2002).
2.3. Leptin
In addition to factors that promote insulin resistance and
related metabolic diseases, there are also mechanisms
known to counterbalance these effects. Among these is
leptin, a 167-amino-acid product of the OB gene predom-
inantly expressed in adipose tissue (Zhang et al., 1994). It
has been described above that defects in fuel partitioning
into adipose tissue, either because of increased adipose
tissue mass or increased lipolysis and circulating free fatty
acids, results in dyslipidemia, hyperglucocorticoidism, in-
sulin resistance and in some cases diabetes. Starting with the
discovery of leptin in 1994 by Zhang et al. (1994), however,
this ‘‘passive’’ view on adipose tissue is rapidly changing
towards the concept that adipose tissue is an active endo-
crine organ involved in the regulation of energy metabolism
and fuel partitioning (Mora and Pessin, 2002). Leptin
circulates in proportion to body adiposity in many species
including primates and rodents (Considine et al., 1996;
Zhang et al., 1994). Among the tissues that express mRNA
encoding the signaling form of leptin receptors are, for
example, adipose tissue, muscle, liver, gastrointestinal tract,
adrenal gland, and a number of regions in the CNS,
including the ventrobasal hypothalamus (Schwartz et al.,
2000). The role played by leptin in the regulation of energy
balance is well addressed by the fact that the hyperphagia,
insulin resistance, and obesity of Zucker rats as well as db/
db mice (Ahima and Flier, 2000; Seeley et al., 1996) are due
to mutations in the signaling variant of leptin receptors [i.e.,
db/db mice or fa/fa Zucker rats]. Mice with a mutation in the
G. van Dijk et al. / European Journal of Pharmacology 480 (2003) 31–42 35ob gene [i.e., ob/ob mice (Ahima and Flier, 2000; Campfield
et al., 1995)] yielding a dysfunctional form of secreted
leptin are extremely obese, insulin-resistant and hyperphagic
as well. Apparently, these animals lack a negative feedback
signal from their fat stores, which would be necessary to
allow appropriate adjustments to disturbances in adipose
tissue mass. Recombinant functional leptin administration
reverses obesity and metabolic derangements only in
rodents that synthesize a deficient form of leptin, but not
in those that have a dysfunctional leptin receptor (Campfield
et al., 1995).
It is becoming increasingly clear that leptin has powerful
insulin-sensitizing capacities. For example, loss of adipose
tissue mass (lipodystrophy) in rodents as well as in
humans, which causes a state of hypoleptinemia, results
in a severe insulin resistance, dyslipidemia, hepatic fat
deposition and potentially diabetes (Ebihara et al., 2001).
Leptin replacement (Ebihara et al., 2001) as well as
transplantation (Gavrilova et al., 2000) of non-mutant fat
are able to reverse some of these abnormalities in lip-
odystrophic mice, and essentially the same data are cur-
rently collected in lipodystrophic humans receiving leptin
therapy (Farooqi, 2003). With the transplantation studies,
however, one needs to caution the fact that transplanted fat
depots are not innervated, as opposed to endogenous fat
(Fliers et al., 2002; Kreier et al., 2002), which may account
for some differences in outcomes among studies. Never-
theless, the insulin resistance syndrome and dyslipidemia
observed in lipodystrophic mice are homologous to those
observed in leptin-deficient ob/ob mice, in spite of the huge
differences in fat deposition among these strains. This
indicates that it is not the difference in fat accumulation
per se underlying these metabolic syndromes, but the
absence of leptin.
2.4. Other factors related to adiposity
Following the discovery of leptin, a number of other genes
and their products were found in adipose tissue with potent
effects on fuel partitioning and metabolism. Among these is
adiponectin (also known as AdipoQ or ACRP30), a highly
conserved gene of which the expression as well its secreted
peptide product into the circulating was found to be down-
regulated in leptin-deficient ob/ob mice (Hu et al., 1996).
Injection of purified adiponectin in mice stimulates h-oxida-
tion in peripheral tissue and promotes fat depletion (Yamau-
chi et al., 2001), body weight loss (Fruebis et al., 2001), and
causes a transient decline in basal glucose levels of ob/ob
mice as well as in non-obese diabetic or streptozotocin-
induced diabetic mice (Berg et al., 2001; Yamauchi et al.,
2001). Adiponectin appears to be down-regulated in obesity,
particularly when the latter is associated with the metabolic
syndrome (Arita et al., 1999). The finding that leptin-defi-
cient ob/ob mice have reduced plasma levels of adiponectin
could imply that leptin up-regulates adiponectin synthesis
and, vice versa, that leptin resistance in obese subjectsunderlies the reduction in adiponectin synthesis. Consistent
with a role for leptin in adiponectin synthesis is the finding
by Zhang et al. (2002) that peripheral leptin treatment
prevented a fall in adiponectin synthesis in adipose tissue
of rats, despite the fact that these rats were anorexigenic and
had a profound loss in body weight. In rats pair-fed to these
leptin-treated animals, a reduction in adiponectin synthesis
was observed, presumably as a result of reduced leptin levels.
Besides adiponectin and leptin, adipose tissue also produces
factors which oppose insulin action. Among these, tumor
necrosis factor a (TNF-a) might be the major candidate as it
is up-regulated in obesity (Uysal et al., 1998), and impairs
insulin action (Hotasmisligil, 1999). Another adipocyte hor-
mone with insulin-desensitizing actions is resistin, but pre-
sumed up-regulation in obesity is highly debated (Steppan
and Lazar, 2002; Way et al., 2001).
In this respect, it is interesting to note that adiponectin
synthesis is down-regulated by glucocorticoids (Fasshauer
et al., 2002), and up-regulated by thiazolidinediones
(Combs et al., 2002; Maeda et al., 2001). Thiazolidine-
diones are a class of insulin-sensitizing drugs, which exert
their antidiabetic effects through a mechanism that involves
activation of the gamma isoform of peroxisome proliferator-
activated receptor (PPAR-g), a nuclear receptor (Spiegel-
man, 1998). Thiazolidinedione-induced activation of PPAR-
g alters the transcription of several genes involved in
glucose and lipid metabolism and energy balance, including
those that code for lipoprotein lipase, fatty acid transporter
protein, adipocyte fatty acid binding protein, fatty acyl-CoA
synthase, malic enzyme, glucokinase and the glucose trans-
porter GLUT4 (Hauner, 2002). High levels of TNF-a as a
result of obesity and/or atherosclerosis suppress adiponectin
synthesis and this effect can also be prevented by thiazoli-
dinediones (Maeda et al., 2001). Through these mecha-
nisms, thiazolidinediones reduce insulin resistance in
adipose tissue, muscle and liver, and are used therapeuti-
cally in type-II diabetic patients. However, PPARg is
predominantly expressed in adipose tissue (Vidal-Puig et
al., 1996). Thus, it is possible that the effect of thiazolidi-
nediones to increase insulin action and normalize associated
metabolic dysregulations in tissues occurs through stimu-
lated adiponectin synthesis and release and/or changes in the
release of other adipose hormones/factors.3. CNS control of peripheral fuel metabolism and insulin
action
While some of the effects of leptin on peripheral insulin
action and metabolism may be attributed to autocrine effects
of leptin on metabolic processes in peripheral tissues (Sieg-
rist-Kaiser et al., 1997), or to the fact that leptin reduces
glucocorticoid secretion at the level of the adrenal gland
(Pralong et al., 1998), a major hypothesis states that leptin
and glucocorticoids regulate energy metabolism and fuel
partitioning via interactions with CNS neuronal networks.
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The spectrum by which glucocorticoids can affect
energy balance is not only restricted to insulin sensitivity,
but in fact, may permit most aspects of the metabolic
syndrome in many genetically obese rodents. For example,
removal of the adrenal glands in Zucker rats causes
profound amelioration of insulin resistance (Freedman et
al., 1986), but also leads to normalization of their plasma
lipid levels and induces leanness (Castonguay et al., 1986).
In addition, Zucker rats reduce their food intake, in
particular that of dietary fat, upon adrenalectomy (Caston-
guay et al., 1986). The latter effect suggests a role of
glucocorticoids mediated via the CNS. An interaction
between glucocorticoids and CNS neuronal networks in-
volved in feeding behavior has been substantiated by
Leibowitz (1990). In this event, the diurnal rise in gluco-
corticoids which normally occurs preceding the active
phase probably underlies an increase in the synthesis in
arcuate hypothalamic neurons of neuropeptide Y (NPY),
i.e., a neuropeptide with remarkably potent stimulatory
effects of food intake (Leibowitz, 1990). Consistent with
an anabolic action of glucocorticoids in the CNS are the
findings of Zakrzewska et al. (1999a) that prolonged
infusion of dexamethasone (i.e., a synthetic glucocorticoid
agonist) over days into the cerebral ventricle of genetically
normal rats induces obesity, hyperphagia and hypertrigly-
ceridemia in these animals, despite their hyperleptinemia.
These effects are probably mediated via NPY, since
chronic glucocorticoid treatment in these animals was
associated with increased synthesis of NPY in the arcuate
hypothalamus. Increased levels of NPY in the paraventric-
ular hypothalamus, which is an important projection area
of arcuate hypothalamic neurons, induce obesity, hyper-
phagia, hypertriglyceridemia and insulin resistance, but
again, these effects rely on central glucocorticoid action
(Zakrzewska et al., 1999b). In addition, increased NPY
levels in the paraventricular hypothalamus cause a shift in
autonomic outflow to a higher parasympathetic activity,
which, for example, leads to elevated insulin responses
during meals, and this contributes to subsequent weight
gain and increased adipose tissue mass as well (Van Dijk
et al., 1994). Since paraventricular NPY is known to
stimulate glucocorticoid secretion (Albers et al., 1990),
interactions among free fatty acids, glucocorticoids, and
paraventricular NPY can easily become self-perpetuating,
and could therefore propel towards development of the
metabolic syndrome, particularly when subjects are fed a
high-fat diet.
3.2. Leptin
Consistent with a role for leptin in the regulation of
adiposity was the finding by Koyama et al. (1998) that
normal lean rats virtually lose all fats when these animals
undergo adenovirus gene transfer of the OB gene leading toelevated endogenous leptin production. This treatment,
however, is not effective in rats with an electrolytic lesion
in the ventrobasal hypothalamus (Koyama et al., 1998),
suggesting that this brain region is required for leptin action.
Furthermore, relatively low doses of leptin given into the
third cerebral ventricle of non-mutant rats (Van Dijk et al.,
1996) and mice (Campfield et al., 1995), and even lower
doses directly into the ventromedial and arcuate hypotha-
lamic nuclei (Satoh et al., 1997), are much more potent to
reduce food intake than when leptin is delivered peripher-
ally. Other evidence pointing in the direction that leptin
interacts with the CNS are findings that third cerebral
ventricular administration of anorexigenic doses of leptin
increases expression of c-Fos (Van Dijk et al., 1996) and
other markers of neuronal activity (Elmquist et al., 1998) in
several CNS regions including the ventrobasal hypothala-
mus. Evidence for a CNS action of leptin on lipid metab-
olism was provided by some of our studies in which normal
lean rats underwent chronic third cerebral ventricular leptin
treatment over several days (Van Dijk et al., 1999). While
producing sustained anorexia, chronic third cerebral ven-
tricular leptin treatment caused rats to lose more fat than a
group of control rats receiving a similar amount of food (i.e.,
pair-fed rats). This appeared to be due to the fact that third
cerebral ventricular leptin treatment accentuated lipid oxi-
dation (measured by indirect calorimetry) relative to pair-fed
controls. This might underlie the observation that plasma
levels of free fatty acids and ketones remained lower than in
pair-fed controls. The finding that third cerebral ventricular
leptin treatment stimulated thermogenesis suggests that part
of the energy arising from increased breakdown of fat and
stimulated h-oxidation is dissipated in the form of heat (Van
Dijk et al., 1999; Van Dijk, 2001). Consistent with these
effects of leptin on metabolism is the finding of Shi et al.
(1998) that chronic third cerebral ventricular leptin-treated
rats become more insulin-sensitive than pair-fed controls.
Essentially the opposite occurs in mice with brain-specific
targeted deletion of leptin receptors (Cohen et al., 2001).
Among others, these mice have markedly elevated fat
accumulation in the liver; a metabolic abberation indicative
of insulin resistance (Cohen et al., 2001). The latter pheno-
type did not occur when leptin signaling, specifically in the
liver, was compromised by tissue-specific deletion (Cohen
et al., 2001). Consistent with the idea that central leptin
signaling is able to regulate hepatic lipid accumulation is the
observation by Cohen et al. (2002) that third cerebral
ventricular leptin treatment in rats is able to down-regulate
hepatic SCD1 transcription.
With respect to the endocrine function of adipose tissue,
we have recently begun to investigate whether leptin given
into the CNS of rats is able to alter adipose hormone
secretion and transcription. Again, rats received chronic
third cerebral ventricular leptin infusion, and, while produc-
ing anorexia and body weight loss, leptin prevented a fall in
the plasma level of adiponectin whereas the plasma adipo-
nectin level decreased by 40% in pair-fed rats. This could
G. van Dijk et al. / European Journal of Pharmacology 480 (2003) 31–42 37not be attributed to peripheral leptin nor insulin levels, since
these levels in third cerebral ventricular leptin-infused rats
were indistinguishable from those in pair-fed controls (see
Fig. 2).
It is currently unknown how leptin via an action in the
CNS is able to regulate adiponectin gene expression or
whether it is able to regulate TNF-a and/or resistin synthesis
and secretion at all (or that of other adipocyte secretory
factors including interleukin 6, vascular endothelial growth
factor, or enzymes such as lipoprotein lipase). We did,
however, observe recently that chronic third cerebral ven-
tricular infusion of leptin in rats caused a fourfold increase
in the mRNA level of PPAR-g in retroperitoneal fat relative
to that in pair-fed controls or ad libitum feeding control rats
(de Vries et al., in preparation). Thus, thiazolidinediones and
increased CNS leptin signaling might affect overlapping
pathways in adipose tissue, involving PPARg activation and
activation of adiponectin synthesis, through which whole-
body insulin action is increased and metabolic functions are
improved. The CNS outflow pathways controlled by leptin,
which are able to affect endocrine activity of adipose tissue,
are currently unraveled. Possible mechanisms might include
alterations in autonomic nervous system outflow to adipose
tissue (Commins et al., 1999; Fliers et al., 2002) and
alterations in the activity of several hypothalamo-pituitary
axes, including thyroid (Pucci et al., 2000), adrenal (Masu-
zaki et al., 2001) and growth hormone (Nam and Lobie,
2000), and gonadal (Chehab, 2000) axes. It is important to
realize, however, that the abovementioned influences can
vary greatly depending on the type of fat deposition (i.e.,
abdominal, subcutaneous or brown fat).Fig. 2. Effect of 7-day third-cerebral ventricular infusion (by use of osmotic
minipumps) of leptin (10 Ag/day) on plasma levels of adiponectin (Ag/ml),
leptin (ng/ml) and insulin (ng/ml) in male Wistar rats. Effects were
compared to animals infused into the third cerebral ventricles with saline
that were either fed ad libitum (control) or received the same daily amount
of food as was daily eaten by the leptin-treated rats (leptinpf). All data are
expressed as average change (F S.E.M.). Asterisk indicates a significant
difference relative to saline treatment.4. Specific neuronal networks involved in peripheral
insulin action and fuel metabolism
As with glucocorticoids, several studies indicate that
leptin mediates its effects on food intake, metabolism and
fuel partitioning through modulatory actions on neuropeptide
producing neuronal cell bodies in the arcuate hypothalamus.
Opposed to the stimulatory effects of glucocorticoids onNPY
synthesis (Zakrzewska et al., 1999a), leptin reduces the
synthesis of NPY as well as its co-synthesized orexigenic
neuropeptide, agouti-related protein (AgRP) (Schwartz et al.,
2000). Another leptin-receptive cell type located in the
arcuate hypothalamus co-synthesizes cocaine-ampheta-
mine related transcript (CART) and pro-opiomelanocortin
(POMC) (Schwartz et al., 2000). From the latter, a-melano-
cyte stimulating hormone (a-MSH) is cleaved. While CART
(Kristensen et al., 1998) and a-MSH (Tsujii and Bray, 1989)
reduce food intake and promote body fat loss when these
neuropeptides are infused into the cerebral ventricles of
experimental animals, leptin consistently up-regulates the
synthesis of these neuropeptides in fasting and leptin-defi-
cient rodents (Schwartz et al., 2000). The neuronal cell bodies
that produce NPY/AgRP and CART/POMC project intra-
hypothalamically as well as extra-hypothalamically (Elm-
quist et al., 1998), andmay affect food intake directly through
changing the sensation of hunger and/or satiety, or via
alterating the activity of downstream neurotransmitter sys-
tem, including, for example, corticotropin-releasing hormone
(Van Dijk, 2001), melanin-concentrating hormone (MCH)
(Tritos and Maratos-Flier, 1999), and the neurotrophin-regu-
lated gene product called VGF (nonacronymic) (Hahm et al.,
2002).
Although a-MSH is one of the many cleavage products of
POMC, it is probably most relevant for regulation of energy
balance relative to other POMC products. a-MSH acts
agonistically on brain melanocortin receptors (Adan and
Gispen, 2000) and competes with AgRP, which is an endog-
enous antagonist on melanocortin receptors (Ollmann et al.,
1997). The melanocortin system received much attention
over the last few years since obesity can occur from different
mutations in it in humans (Farooqi, 2003; Vaisse et al., 2000).
In addition, mice with a targeted deletion in the gene encod-
ing the melanocortin MC4 receptor become morbidly obese
as well (Huszar et al., 1997). The melanocortin MC4 receptor
is widely expressed in the CNS, including in regions involved
in the control of ingestive behavior, sympathetic outflow to
peripheral tissues and organs, and neuroendocrine axes (Liu
et al., 2003). There are several lines of evidence demonstrat-
ing the involvement of the brain melanocortin system in
leptin action. The first one came from our rat study in which
the anorexigenic effect of third cerebral ventricular injected
leptin was prevented by co-administration of the melanocor-
tinMC3/4 receptor antagonist, SHU9119, in a dose which was
by it self unable to alter food intake (Seeley et al., 1997).
Others found that third cerebral ventricular SHU9119 admin-
istration was able to block the effects of co-administered
G. van Dijk et al. / European Journal of Pharmacology 480 (2003) 31–4238leptin to stimulate sympathetic outflow to peripheral organs
(Haynes et al., 1999) and to stimulate brown-adipose tissue
thermogenesis (Satoh et al., 1998). We have observed that
chronic third cerebral ventricular SHU9119 treatment in rats
produces hyperphagia, obesity and hypothermia, despite
peripheral hyperleptinemia (Adage et al., 2001). Recently,
we found that the opposite occurs when an agonist of the
melanocortin MC4 receptor is given chronically into the third
cerebral ventricle of rats over several days. In addition, we
observed that, analogous to the effects of central leptin
infusion, chronic infusion of the melanocortin MC4 receptor
agonist into the third cerebral ventricle caused an increase in
the circulating level of adiponectin. Consistent with this is the
finding of the group of Rosetti (Obici et al., 2001) that
increased activity of brain melanocortin receptors by third
cerebral ventricular a-MSH infusion augments insulin-in-
duced glucose uptake in peripheral tissue, whereas third
cerebral ventricular administration of SHU9119 causes the
opposite effect (Obici et al., 2001). The mechanisms by
which increased CNS leptin signaling, presumably via in-
creased brain melanocortin receptor activity, increases insulin
action and exerts other mentioned metabolic effects are as yet
unknown. If any, it appears not to rely on the integrity of the
hypothalamo-pituitary adrenal axis since chronic alterations
in brain melanocortin receptor activity are not associated with
changes in glucocorticoid levels (Huszar et al., 1997), nor
does adrenal insufficiency prevent obesity associated with
low brain MC receptor activity (Yaswen et al., 1999). In
contrast, hyperactivity of the NPY system in rats is known to
cause hyperphagia, obesity, and insulin resistance, as well as
hypercorticoidism (Sainsbury et al., 1997). In this case, the
obesity as well as insulin resistance were attenuated when
NPY is given into the third cerebral ventricle rats which had
their adrenals removed (Sainsbury et al., 1997). Finally, also
hyperactivity of the MCH systems leads to obesity and
insulin resistance (Ludwig et al., 2001), but the mechanism
is unclear. MCH neurons, however, have very widespread
connection in the CNS, including the autonomic pregan-
glionics (Elias et al., 1998), and could therefore influence
peripheral fuel fluxes through altered autonomic tone. Taken
together, pivotal CNS neuronal networks are involved in
leptin signaling, and reduce ingestion as well modulate
autonomic and neuroendocrine outflow to facilitate lipid
breakdown and increase peripheral insulin sensitivity. Dis-
turbances in these mechanisms can lead to different forms of
obesity and associated metabolic syndromes including insu-
lin resistance.5. Conclusion and remarks
It has been mentioned above that leptin can, via an action
in the CNS, alter endocrine activity of adipose tissue leading
to increased adiponectin release, which in turn increases
peripheral lipid oxidation and insulin sensitivity. Given the
surplus of high-palatable foods in our western-industrializedsocieties, however, the homeostatic feedback systems that
regulate energy balance can propably easily be overridden
and lead to increases in fat mass. Since increased fat mass,
and in particular that of the abdominal compartment, exposes
the liver to elevated levels of free fatty acids, this could
amplify HPA axis activity leading to elevated levels of
glucocorticoids. In turn, glucocorticoids can contribute to
reduced insulin action in peripheral tissues and organs, or by
directly down-regulating adiponectin release. Within the
CNS, glucocorticoids can reduce leptin action by regulating
the activity of CNS neuropeptide involved in food intake,
neuroendocrine outflow and metabolism, generally in the
opposite direction (e.g., Zakrzewska et al., 1999a), or poten-
tially by down-regulating the intraneuronal signaling cascade
for leptin (Madiehe et al., 2001; Makimura et al., 2000).
Together, these effects might be a major cause of leptin
resistance (Zakrzewska et al., 1997), and thus ultimately
have an impact on endocrine activity of adipose tissue,
peripheral metabolic pathways, and whole body insulin
sensitivity. Thus, according to this scheme, feeding a high-
fat diet puts subjects at risk for developing obesity and related
metabolic diseases. Psychological stress leading to chroni-
cally elevated levels of glucocorticoids is probably another,
or additional, cause of obesity and related metabolic diseases
(Ur et al., 1996; Bjorntorp, 2001). At this point, the biological
relevance of this mechanism may not be clear. However,
recent studies from our laboratory have shown that rats fed a
high-fat diet are less affected by psychosocial stress in terms
of fever development, disturbances in locomotor activity and
feeding behavior (Buwalda et al., 2001) than rats fed a high-
carbohydrate diet. At a later stage, however, the high-fat-
feeding rats, but not the carbohydrate-feeding rats, develop
insulin resistance (Van Dijk and Buwalda, 2003). It may
therefore be suggested that the increased risk of obesity and
related metabolic diseases as a cause of stress and high-fat
feeding is simply a trade-off, which may not necessarily have
hampered the evolutionary success of humans as well as other
species.Acknowledgements
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